Artefenomel/ Ferroquine

Sanofi

Product vision
  • Novel agents in combination for treatment including resistant strains; single-dose potential
MoA
  • Artefenomel (OZ439): novel, synthetic trioxolane 

  • Ferroquine (FQ), belonging to 4-aminoquinolines: inhibition of haem detoxification

Key features

Artefenomel

  • Fast killing of parasites 

  • 800mg human dose stays above Minimal Parasiticidal Concentration for >8 days

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

Ferroquine

  • Long duration of plasma exposure

Challenges
  • OZ439 food effect/formulation

Status
  • Phase llb combination study ongoing
Next milestone
  • Phase llb study completion

Previously
  • 2018- operational development transferred from Sanofi to MMV
  • Discovery partnership between MMV, Monash, Nebraska and Swiss Tropical Institute
  • Ferroquine discovered by CNRS Lille
MMV Project Director
  • Dr Florian Wartha